QRSL1 and hematologic disorder: As precision medicine advances, health policies need to consider ethical implications related to genetic testing, access to targeted therapies, and ensuring equitable healthcare delivery for individuals with specific genetic markers or mutations related to GATA factors and hematological malignancies.